Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Gevokizumab"'
Publikováno v:
Pharmaceutics, Vol 16, Iss 9, p 1129 (2024)
The aim of the present study was to develop and evaluate the performance of a methodology to estimate the population pharmacokinetic (PK) parameters along with the inter-individual variabilities (IIVs) from patients’ reported aggregate concentratio
Externí odkaz:
https://doaj.org/article/221be78ee30247ef98cc3af306819570
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundThe cytokine interleukin (IL)-1 plays a pivotal role in immune-mediated disorders, particularly in autoinflammatory diseases. Targeting this cytokine proved to be efficacious in treating numerous IL-1-mediated pathologies. Currently, three
Externí odkaz:
https://doaj.org/article/5598cba60f3c4dc3805be2568e4f732a
Publikováno v:
Current Reviews in Clinical and Experimental Pharmacology. 16:219-227
Background: Interleukin-1 (IL-1) is a pro-inflammatory cytokine that is produced by endothelial cells, smooth muscle cells, and macrophages. It is an important regulator of a complex humoral and cellular inflammatory response. IL-1β is known to be i
Autor:
Giuseppe Lopalco, Gerardo Di Scala, Carlo Salvarani, Claudia Fiorillo, Elena Silvestri, Amedeo Amedei, Alessandra Bettiol, Luca Cantarini, Giacomo Emmi, Alessandra Soriano, Matteo Becatti
Publikováno v:
Rheumatology International. 39:971-990
Behçet's syndrome (BS) is a chronic (auto)-inflammatory disorder characterized by different clusters of symptoms, including mucocutaneous and ocular involvements. Interleukin-1 inhibitors anakinra (ANA), canakinumab (CAN), and gevokizumab (GEV) repr
Autor:
Hana Malcova, Zuzana Strizova, Tomas Milota, Ilja Striz, Anna Sediva, Dita Cebecauerova, Rudolf Horvath
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
Frontiers in Immunology
Frontiers in Immunology
Autoinflammatory diseases (AIDs) represent a rare and heterogeneous group of disorders characterized by recurrent episodes of inflammation and a broad range of clinical manifestations. The most common symptoms involve recurrent fevers, musculoskeleta
Autor:
Charles A. Dinarello
Publikováno v:
Curr Otorhinolaryngol Rep
To provide evidence that therapeutic blockade of IL-1 can provide benefit for patients with hearing loss. In this review, we assess clinical trials of the IL-1 receptor antagonist (anakinra), the soluble IL-1 receptor (rilonacept), antibodies to inte
Autor:
Hana Malcova, Tomas Milota, Zuzana Strizova, Dita Cebecauerova, Ilja Striz, Anna Sediva, Rudolf Horvath
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 11 (2021)
Frontiers in Pharmacology, Vol 11 (2021)
Polygenic autoinflammatory diseases (AIDs), such as systemic juvenile idiopathic arthritis (sJIA), adult-onset Still's disease, Kawasaki disease, idiopathic recurrent pericarditis (IRP), Behçet’s Syndrome, Crystal-induced arthropatihes such as gou
Autor:
I. Striz
Publikováno v:
Clinical Science. 131:2241-2256
Interleukin 1 (IL-1) family is a group of cytokines with multiple local and systemic effects, which regulates both innate and adaptive immune responses. Generally, most IL-1 family cytokines express prevailing pro-inflammatory activities (IL-1α, IL-
Autor:
Karen R Armbrust, Jared E. Knickelbein, David Valent, Robert B. Nussenblatt, William R Tucker, H. Nida Sen, Nirali Bhatt, Dominic Obiyor
Publikováno v:
American Journal of Ophthalmology. 172:104-110
Purpose To evaluate the safety and potential efficacy of gevokizumab, an anti-interleukin 1β (IL-1β) monoclonal antibody, in the treatment of active, noninfectious, non-necrotizing anterior scleritis. Design Phase 1/2, open label, nonrandomized, pr